Zoetis Inc. (NYSE:ZTS) Shares Acquired by Fulcrum Capital LLC

Fulcrum Capital LLC lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 49,243 shares of the company’s stock after acquiring an additional 642 shares during the period. Zoetis accounts for about 2.1% of Fulcrum Capital LLC’s investment portfolio, making the stock its 16th largest holding. Fulcrum Capital LLC’s holdings in Zoetis were worth $9,621,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in ZTS. Sarasin & Partners LLP boosted its holdings in shares of Zoetis by 546.3% during the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after purchasing an additional 1,904,899 shares during the last quarter. Swedbank AB acquired a new position in Zoetis in the first quarter valued at $210,815,000. Marshall Wace LLP boosted its holdings in Zoetis by 7,608.6% in the second quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock valued at $144,874,000 after acquiring an additional 824,843 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Zoetis by 1.0% in the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after acquiring an additional 414,605 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its holdings in Zoetis by 178.2% in the first quarter. Canada Pension Plan Investment Board now owns 639,352 shares of the company’s stock valued at $108,185,000 after acquiring an additional 409,522 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 0.3 %

Shares of NYSE ZTS opened at $188.99 on Thursday. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The firm has a market cap of $85.62 billion, a price-to-earnings ratio of 36.98, a PEG ratio of 2.94 and a beta of 0.89. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The stock’s 50-day simple moving average is $189.23 and its 200-day simple moving average is $177.58.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion for the quarter, compared to analyst estimates of $2.31 billion. During the same period in the previous year, the company earned $1.41 earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. As a group, equities analysts anticipate that Zoetis Inc. will post 5.83 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s dividend payout ratio is currently 33.86%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus lifted their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, BTIG Research boosted their price objective on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.